Asia Biopharma Manufacturing 2028

Asia-Pacific is strengthening its position as a major hub for biopharmaceutical manufacturing, driven by growing biologics pipelines, expanding production capacity and increasing investment in advanced manufacturing technologies. Across the region, manufacturers are adopting process intensification, automation, AI and digital technologies to improve productivity, flexibility and manufacturing resilience.

Singapore is one of Asia-Pacific's established biopharmaceutical manufacturing hubs, home to manufacturing operations from many of the world's leading biopharma companies. Continued investments in biologics, vaccines, ADCs and advanced manufacturing are further strengthening Singapore's role in the regional and global biopharmaceutical supply chain.

Taking place on 16–17 May 2028 in Singapore, Asia Biopharma Manufacturing 2028 will bring together biopharma manufacturers, biotech companies, CDMOs and technology providers from Singapore, South Korea, Japan, China, India, Southeast Asia, Australia and across the wider Asia-Pacific region.

The conference will explore the future of upstream and downstream processing, process intensification, analytical technologies and PAT, scale-up and technology transfer, AI and digital manufacturing, automation, advanced facilities and sustainable manufacturing — providing a focused platform to exchange expertise, discover new technologies and advance the next generation of biopharmaceutical manufacturing across APAC.